COMMUNIQUÉS West-GlobeNewswire

-
DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors
09/07/2025 -
MEME Coins Inc. Finalizes DOG Token Acquisition from Tipestry Inc.
09/07/2025 -
Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee Group in Switzerland
09/07/2025 -
Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland
09/07/2025 -
Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN)
09/07/2025 -
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock
09/07/2025 -
Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity
08/07/2025 -
LeMaitre Will Announce Second Quarter 2025 Earnings Results August 5, 2025
08/07/2025 -
Lixte Biotechnology Holdings, Inc. Announces the Closing of $1.5 Million Registered Direct Offering
08/07/2025 -
RxSight, Inc. Announces Preliminary Second Quarter 2025 Revenue and Revised 2025 Guidance
08/07/2025 -
Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
08/07/2025 -
Enovis to Host Second Quarter 2025 Results Conference Call on August 7th
08/07/2025 -
BrightSpring Health Services, Inc. to Announce Second Quarter 2025 Financial Results on August 1, 2025
08/07/2025 -
Genfit : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial
08/07/2025 -
Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
08/07/2025 -
New ExoPTEN Preclinical Study Indicates Significant Improvement in Walking Quality in Spinal Cord Injury Model
08/07/2025 -
Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock
08/07/2025 -
Vireo Growth Inc. Completes Loan Refinancing and Upsize With a Bank Led Syndicate Arranged by CEO, John Mazarakis
08/07/2025 -
Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts
08/07/2025
Pages